Platelet aggregation in hypertension and the effects of antihypertensive treatment

Journal of Hypertension

Volumn 6, Issue 4, 1988, Pages 263-269

  Nyrop, Mette ^a   Zweifler, Andrew J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Aggregatory synergism; Antihypertensive treatment; Beta adrenergic blockers; Calcium channel blockers; Hypertension; Platelet aggregation

Indexed keywords

DILTIAZEM; NIFEDIPINE; NISOLDIPINE; PROPRANOLOL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; REVIEW; THROMBOCYTE AGGREGATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HUMAN; HYPERTENSION; PLATELET AGGREGATION; PROPRANOLOL;

EID: 0023916026     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-198804000-00001     Document Type: Review

References (48)

1. McMahon SW, Cutler JA, Furberg CD, Payne GH: The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: A review of randomized controlled trials. Prog Cardiovasc Dis 1986, 29 (suppl 1):99–118.
2. Ross R, Glomset JA: The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976, 295:420–425.
3. Kerry R, Scrutton MC, Wallis RB: Mammalian platelet adrenore-ceptors. Br J Pharmacol 1984, 81:91–102.
4. Zucker MB, Nachmias VT: Platelet activation. Arteriosclerosis 1985, 5:2–18.
5. Jakobs KH, Saur W, Schultz G: Characterization of alpha-and beta-adrenergic receptors linked to human platelet adeny-late cyclase. Naunyn Schmiedebergs Arch Pharmacol 1978, 302:285–291.
6. Kerry R, Scrutton MC: Platelet beta-adrenoreceptors. Br J Pharmacol 1983, 79:681–691.
7. + mobilizing hormones. Trends in Biochemical Sciences 1984, 9:420–421.
8. + thresholds and Ca-independent activation for shape-change and secretion. FEBS lett 1982, 148:21–26.
9. Rink TJ, Hallam TJ: What turns platelets on? Trends in Biochemical Sciences 1984, 9:215–219.
10. Mehta J, Mehta P: Platelet function in hypertension and effect of therapy. Am J Cardiol 1981, 47:331–334.
11. Ashida T, Tanaka T, Yokouchi M, Kuramochi M, Deguchi F, Kimura G, Kojima S, Ito K, Ikeda M: Effect of dietary sodium on platelet alpha-2-adrenergic receptors in essential hypertension. Hypertension 1985, 7:972–978.
12. Brodde OE, Stuka N, Demuth V, Fesel R, Bergerhausen J, Daul A, Bock KD: Alpha- and beta-adrenoreceptors in circulating blood cells of essential hypertensive patients. Increased receptor density and responsiveness. Clin Exp Hypertens [A] 1985, 7:1135–1150.
13. DeClerck F: Blood platelets in human essential hypertension. Agents Actions 1986, 18:563–580.
14. Vlachakis ND, Aledort L: Hypertension and propranolol therapy: Effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 1980, 45:321–325.
15. Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K: Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984, 6:840–843.
16. Hollister AS, Onrot J, Lonce S, Nadeau JHJ, Robertson D: Plasma catecholamine modulation of alpha-2 adrenoreceptor agonist affinity and sensitivity in normotensive and hypertensive human platelets. J Clin Invest 1986, 77:1416–1421.
17. Tofler GH, Brezinski D, Schafer Al, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE: Concurrent morning increase in platelet aggregability and the risk of myo-cardial infarction and sudden cardiac death. N Engl J Med 1987, 316:1514–1518.
18. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwald E, MILIS study group: Circadian variation in the frequency of onset of acute myocar-dial infarction. N Engl J Med 1985, 313:1315–1322.
19. Muller JE, Ludmer PL, Willich SN, Tofler GH, Aylmer G, Klangos I, Stone PH: Circadian variation in the frequency of sudden cardiac death. Circulation 1987, 75:131–138.
20. Ardlie NG, McGuiness JA, Garrett JJ: Effect on human platelets of catecholamines at levels achieved in the circulation. Atherosclerosis 1985, 58:251–259.
21. Born GVR, Kratzer MAA: Source and concentration of extracellular adenosine triphosphate during haemostases in rats, rabbits and man. J Physiol 1984, 354:419–424.
22. Kamal LA, Quan-Bui KHL, Meyer P: Decreased uptake of 3-H-serotonin and endogenous content of serotonin in blood platelets in hypertensive patients. Hypertension 1984, 6:568–573.
23. Sharma A, Chandra M: Involvement of catecholamines and serotonin in human hypertension. Pharmacol Res Commun 1985, 17:565–574.
24. Sang KHLQ, Laude D, Devynck MA: Platelet cytosolic free Ca-2+ concentration and serotonin content in essential hypertension. J Hypertension 1987, 5:237–240.
25. Valtier D, Guicheney P, Baudouin-Legros M, Meyer P: Platelets in human essential hypertension: In vitro hyperreactivity to thrombin. J Hypertension 1986, 4:551–555.
26. Ding YA, Maclntyre DE, Kenyon CJ, Semple PF: Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost 1985, 54:717–720.
27. Moore TJ, Williams GH: Angiotensin II receptors on human platelets. Circ Res 1981, 51:314–320.
28. Thibonnier M, Roberts JM: Characterization of human platelet vasopressin receptors. J Clin Invest 1985, 76:1857–1864.
29. Vittet D, Rondot A, Cantau B, Launay JM, Chevillard C: Nature and properties of human platelet vasopressin receptors. Biochem J 1986, 233:631–636.
30. Grant JA, Scrutton MC: Positive interaction between agonists in the aggregation response of human blood platelets: Interaction between ADP, adrenaline and vasopressin. Br J Haematol 1980, 44:109–125.
31. Vlachakis ND, Aledort L: Platelet aggregation in rélationship to plasma catecholamines in patients with hypertension. Atherosclerosis 1979, 32:451–460.
32. Frishman WH, Weksler B, Christodoulou JP, Smithen C, Killip T: Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 1974, 50:887–896.
33. Mehta J, Mehta P, Pepine CJ: Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. Circulation 1978, 58:881–886.
34. Ring ME, Corrigan JJ, Fenster PE: Antiplatelet effects of oral diltiazem, propranolol and their combination. Clin Res 1987, 35:116 (abstract).
35. Weksler BB, Gillick M, Pink J: Effect of propranolol on platelet function. Blood 1977, 49:185–196.
36. Campbell WB, Johnson AR, Callahan KS, Graham RM: Antiplatelet activity of beta-adrenergic antagonists: Inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. Lancet 1981, ii:1382–1384.
37. Kerry R, Scrutton MC, Wallis RB: Beta-adrenoreceptor antagonists and human platelets. Relationship of effects to lipid solubility. Biochem Pharmacol 1984, 33:2615–2622.
38. Hansen KW, Klysner R, Geisler A, Knudsen JB, Glazer S, Gormsen J: Platelet aggregation and beta blockers (letter). Lancet 1982, i:224–225.
39. Small M, Douglas JT, Aherne GW, Orr M, Lowe GDO, Forbes CD, Prentice CRM: Effects of the non-selective beta-adrenoreceptor blocking agent, carteolol, on platelet function, blood coagulation and viscosity. Thromb Res 1982, 25:351–360.
40. Winther K, Knudsen JB, Gormsen J, Jensen J: Effect of metoprolol and propranolol on platelet aggregation and cAMP level in hypertensive patients. Eur J Clin Pharmacol 1986, 29:561–564.
41. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J 1985, 291:97–104.
42. The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981, 304:801–807.
43. Dale J, Landmark KH, Myhre E: The effects of nifedipine, a calcium antagonist, on platelet function. Am Heart J 1983, 105:103–105.
44. Jones CR, Pasanisi F, Elliott HL, Reid JL: Effects of verapamil and nisoldipine on human platelets. In vivo and in vitro studies. Br J Clin Pharmacol 1985, 20:191–196.
45. Addonizio VP, Fisher CA, Strauss JF, Edmunds LH: Inhibition of human platelet function by verapamil. Thromb Res 1982, 28:545–556.
46. Addonizio VP, Fisher CA, Strauss JF, Wachtfogel YT, Colman RW, Josephson ME: Effects of verapamil and diltiazem on human platelet function. Am J Physiol 1986, 250:H366–H371.
47. Johnson GJ, Leis LA, Francis GS: Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha-2-adrenergic receptors and thromboxane A-2-induced aggregation of human platelets. Circulation 1986, 73:847–854.
48. + uptake in human blood platelets. Am J Physiol 1980 239:H483–H488.